The Journal of Immunology, Vol 141, Issue 2 410-416, Copyright © 1988 by American Association of Immunologists

ARTICLES

Suppression of B cell function by methotrexate and trimetrexate. Evidence for inhibition of purine biosynthesis as a major mechanism of action

GJ Rosenthal, GW Weigand, DR Germolec, JA Blank and MI Luster
Systemic Toxicology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709.

Methotrexate (MTX) is a widely used drug in the treatment of a variety of human neoplasms. Trimetrexate (TMQ) is a lipid-soluble quinazoline derivate of MTX that, unlike MTX, is not dependent upon membrane folate transport for cellular entry. A number of studies have demonstrated that MTX and, more recently, TMQ possess potent immunosuppressive properties. To examine the cellular events associated with the immunomodulatory effects of anti-folates on humoral immunity, a murine B cell maturation model was used. In vitro, MTX and TMQ reduced the number of antibody-forming cells to SRBC, as well as IgM production. B cells stimulated with anti-Ig demonstrated a dose-related suppression in [3H]UdR incorporation after addition of either drug, suggestive of a decrease in de novo DNA synthesis. B cell activation events preceding S phase were also suppressed by both anti-folates, as evidenced by inhibition of RNA synthesis. However, neither drug affected surface expression of Ia Ag nor inositol phosphate accumulation. Addition of TdR caused a slight non-significant increase in the antibody-forming cell response in the presence of 10(-7) M MTX. However, addition of hypoxanthine or adenine, but not guanine, resulted in complete restoration. Timed addition revealed that the ability of MTX to suppress antibody responses was diminished if added after 48 h of culture, similar to the reversal of this suppression mediated by hypoxanthine. Cell cycle analysis of LPS-stimulated B lymphocytes demonstrated that both drugs modulated events preceding, as well as during, the S phase. The present studies suggest that although drug- induced impairments in dTMP biosynthesis may be responsible for deficient lymphoid proliferation, anti-folate-induced impairment in purine biosynthesis is a major mechanism in anti-folate-induced suppression of humoral immunity.

This article has been cited by other articles:

				F. Bacal, G. L. Sodre, D. A. Fernandes, V. D. Aiello, N. Stolf, E. Bocchi, and G. Bellotti Methotrexate in acute persistent humoral rejection: an option for graft rescue Ann. Thorac. Surg., August 1, 2003; 76(2): 607 - 610. [Abstract] [Full Text] [PDF]

				O J Rackham, J A Sills, and J E Davidson Immunoglobulin levels in methotrexate treated paediatric rheumatology patients Arch. Dis. Child., August 1, 2002; 87(2): 147 - 148. [Abstract] [Full Text] [PDF]

				V. Lapierre, A. Auperin, H. Tayebi, J. Chabod, P. Saas, M. Michalet, S. Francois, F. Garban, C. Giraud, D. Tramalloni, et al. Increased presence of anti-HLA antibodies early after allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood hematopoietic stem cell transplantation compared with bone marrow transplantation Blood, July 30, 2002; 100(4): 1484 - 1489. [Abstract] [Full Text] [PDF]

				V. Lapierre, N. Oubouzar, A. Auperin, D. Tramalloni, H. Tayebi, E. Robinet, M. Kuentz, D. Blaise, O. Hartmann, P. Herve, et al. Influence of the hematopoietic stem cell source on early immunohematologic reconstitution after allogeneic transplantation Blood, May 1, 2001; 97(9): 2580 - 2586. [Abstract] [Full Text] [PDF]

				P. Ferraro, M. Carrier, M. White, G. B. Pelletier, and L. C. Pelletier Antithymocyte Globulin and Methotrexate Therapy of Severe or Persistent Cardiac Allograft Rejection Ann. Thorac. Surg., August 1, 1995; 60(2): 372 - 376. [Abstract] [Full Text]